Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 6/20 | 0.40 |
| ▸ | MTOR | P42345 | 8/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.38 |
| ▸ | ATRIP | Q8WXE1 | 4/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24024154 | 0.90 | ATR (0.45) | ATRMTORPIK3CAPIK3CDATRIP | |
| SCHEMBL24024155 | 0.86 | ATR (0.40) | ATRMTORPIK3CAPIK3CDATRIP | |
| SCHEMBL24024160 | 0.85 | ATR (0.38) | ATRMTORPIK3CAPIK3CDATRIP | |
| SCHEMBL24024138 | 0.84 | ATR (0.41) | ATRMTORPIK3CAPIK3CDATRIP | |
| SCHEMBL29738249 | 0.80 | MTOR (0.48) | ATRMTORPIK3CAATRIPBRD4 | |
| SCHEMBL23408532 | 0.80 | MTOR (0.48) | ATRMTORPIK3CAATRIPBRD4 | |
| SCHEMBL24024124 | 0.80 | ATR (0.37) | ATRMTORPIK3CAPIK3CDATRIP | |
| SCHEMBL24024163 | 0.78 | ATR (0.45) | ATRMTORATRIPBRD4CHEK1 | |
| SCHEMBL19195025 | 0.78 | ATR (0.63) | ATRATRIP | |
| SCHEMBL25700448 | 0.78 | ATR (0.39) | ATRMTORPIK3CAPIK3CDATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355123-A1 | 5-Morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives | MERCK PATENT GMBH (DE) | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355123-A1 | 5-Morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives | ATR, CDK1, CDKN1A | ATR 1/4885MTOR 500/4885PIK3CA 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.